Affordable Access

deepdyve-link
Publisher Website

Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors
  • Mulder, Renée L
  • van Dalen, Elvira C
  • Van den Hof, Malon
  • Bresters, Dorine
  • Koot, Bart Gp
  • Castellino, Sharon M
  • Loke, Yoon
  • Leclercq, Edith
  • Post, Piet N
  • Caron, Huib N
  • Postma, Aleida
  • Kremer, Leontien Cm
Type
Published Article
Journal
The Cochrane database of systematic reviews
Publication Date
Jan 01, 2011
Issue
7
Identifiers
DOI: 10.1002/14651858.CD008205.pub2
PMID: 21735424
Source
Medline
License
Unknown

Abstract

The prevalence of hepatic late adverse effects ranged from 7.9% to 52.8% when selecting studies with an adequate outcome definition. It has not been established which childhood cancer treatments result in hepatic late adverse effects. There is a suggestion that chronic viral hepatitis increases the risk of hepatic late adverse effects. More well-designed studies are needed to reliably evaluate the prevalence of, and risk factors for, hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Report this publication

Statistics

Seen <100 times